Luke Evnin
December 18, 2023 07:00 AM EST
R&D

Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Andrew Dunn

Senior Biopharma Correspondent

Over three decades of in­vest­ing, Luke Evnin has backed and ad­vised dozens of biotechs de­vel­op­ing med­i­cines. Now, the long­time VC is turn­ing his know-how and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times